Your session is about to expire
← Back to Search
GD2-CAR-expressing Autologous T-lymphocytes for Neuroblastoma
Study Summary
This trial is testing an immune cell therapy to see if it is effective in treating patients with osteosarcoma or neuroblastoma.
- Neuroblastoma
- Osteosarcoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What health risks can be associated with GD2-CAR-expressing Autologous T-lymphocytes?
"The safety of GD2-CAR-expressing Autologous T-lymphocytes is thought to be a 1, as this Phase 1 trial only has limited data supporting its efficacy and security."
What therapeutic purpose is GD2-CAR-expressing Autologous T-lymphocytes typically used for?
"GD2-CAR expressing autologous T-lymphocytes is a therapeutic option for multiple sclerosis, as well as various forms of lymphoma and leukemia, myelocytic disease, acute leukemias, and retinoblastoma."
How successful have previous experiments been involving GD2-CAR-expressing Autologous T-lymphocytes?
"First examined at the City of Hope Comprehensive Cancer Center in 1997, GD2-CAR-expressing Autologous T-lymphocytes has been subject to 1275 clinical trials. Currently 889 studies are recruiting participants with many located within Madison, Wisconsin."
How many individuals are included in this research experiment?
"Affirmative. According to clinicaltrials.gov, recruitment for this experiment is ongoing after first being posted on June 11th 2021 and last updated July 15th 2022. 67 individuals are required from 3 research centres in total."
Has recruitment for this experiment begun yet?
"Agreed. The clinicaltrials.gov website indicates that, as of the 15th July 2022, this medical trial is still searching for 67 volunteers from 3 separate locations to participate in their research. This study was initially posted on June 11th 2021."
Share this study with friends
Copy Link
Messenger